[go: up one dir, main page]

MX2016012168A - Formulacion adyuvante no toxica que comprende una composicion de liposoma que contiene monofosforil-lipido a (mpla) y una saponina. - Google Patents

Formulacion adyuvante no toxica que comprende una composicion de liposoma que contiene monofosforil-lipido a (mpla) y una saponina.

Info

Publication number
MX2016012168A
MX2016012168A MX2016012168A MX2016012168A MX2016012168A MX 2016012168 A MX2016012168 A MX 2016012168A MX 2016012168 A MX2016012168 A MX 2016012168A MX 2016012168 A MX2016012168 A MX 2016012168A MX 2016012168 A MX2016012168 A MX 2016012168A
Authority
MX
Mexico
Prior art keywords
mol
saponin
liposome composition
mpla
adjuvant formulation
Prior art date
Application number
MX2016012168A
Other languages
English (en)
Inventor
R Alving Carl
Beck Zoltan
Original Assignee
The Government Of The Us Secretary Of The Army
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Government Of The Us Secretary Of The Army filed Critical The Government Of The Us Secretary Of The Army
Publication of MX2016012168A publication Critical patent/MX2016012168A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

En la presente se proporciona una formulación adyuvante que comprende una composición de liposoma que contiene monofosforil-lípido A (MPLA) y una saponina (por ejemplo QS-21), en donde la composición de liposoma comprende (i) una bicapa de lípido que comprende fosfolípidos en la cual las cadenas de hidrocarburos tienen una temperatura de fusión en agua de = 23°C e (ii) colesterol a una concentración de por ciento en mol mayor de aproximadamente 50% (mol/mol), preferentemente de aproximadamente 55% a aproximadamente 71% (mol/mol), de manera más preferente de aproximadamente 55% (mol/mol). La formulación adyuvante exhibe toxicidad mínima de ya sea lípido A o saponina.
MX2016012168A 2014-03-25 2015-03-25 Formulacion adyuvante no toxica que comprende una composicion de liposoma que contiene monofosforil-lipido a (mpla) y una saponina. MX2016012168A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461970118P 2014-03-25 2014-03-25
PCT/US2015/022461 WO2015148648A1 (en) 2014-03-25 2015-03-25 Non-toxic adjuvant formulation comprising a monophosphoryl lipid a (mpla)-containing liposome composition and a saponin

Publications (1)

Publication Number Publication Date
MX2016012168A true MX2016012168A (es) 2017-04-25

Family

ID=52829375

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016012168A MX2016012168A (es) 2014-03-25 2015-03-25 Formulacion adyuvante no toxica que comprende una composicion de liposoma que contiene monofosforil-lipido a (mpla) y una saponina.

Country Status (11)

Country Link
US (1) US10434167B2 (es)
EP (1) EP3122380B1 (es)
JP (1) JP6608422B2 (es)
KR (1) KR102242875B1 (es)
CN (1) CN107124869B (es)
AU (1) AU2015236106A1 (es)
CA (1) CA2943190A1 (es)
MX (1) MX2016012168A (es)
RU (1) RU2016141622A (es)
SG (2) SG11201607396WA (es)
WO (1) WO2015148648A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3015639A1 (en) * 2016-03-09 2017-09-14 Technion Research And Development Foundation Ltd. Liposomal formulations and methods of using same in agriculture
JP6661454B2 (ja) * 2016-04-21 2020-03-11 株式会社東海理化電機製作所 表示装置、表示板の製造方法
WO2018201022A1 (en) * 2017-04-28 2018-11-01 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Compositions and methods for vaccine delivery
CN107669692B (zh) * 2017-09-07 2020-09-29 中国人民解放军第二军医大学 Mpla在制备电离辐射致肠道损伤防治药物中的应用
KR102755593B1 (ko) * 2017-09-08 2025-01-20 액세스 투 어드밴스드 헬스 인스티튜트 사포닌을 포함하는 리포솜 제형 및 사용 방법
WO2020243166A1 (en) * 2019-05-28 2020-12-03 The Regents Of The University Of California Th1-polarizing adjuvants for enhancing immunogenicity of hiv antigens
CN110613844B (zh) * 2019-10-23 2024-02-27 中国医学科学院生物医学工程研究所 一种迷你联合佐剂纳米颗粒及其制备方法和应用
CN114901275A (zh) 2019-12-20 2022-08-12 纳米医疗有限公司 可用于治疗癌症的含有Toll样受体(“TLR”)激动剂前药的配制和/或共同配制的脂质体组合物及其方法
KR102738033B1 (ko) * 2020-06-30 2024-12-05 아이진 주식회사 양이온성 리포좀을 포함하는 사포닌의 용혈 억제용 조성물
GB2600468A (en) 2020-10-30 2022-05-04 Excivion Ltd Adjuvant composition
CN112546233A (zh) * 2020-12-25 2021-03-26 常州大学 一种负载水不溶性免疫调节分子的透明质酸复合材料及其制备方法
CN114366810B (zh) * 2022-02-15 2024-11-22 中国人民解放军陆军军医大学 一种可高效诱导体液和细胞免疫的天然微生物和植物来源复合双佐剂及其制备方法和应用
EP4493153A1 (en) 2022-03-14 2025-01-22 Pfizer Inc. Methods for producing an adjuvant
WO2024069420A2 (en) 2022-09-29 2024-04-04 Pfizer Inc. Immunogenic compositions comprising an rsv f protein trimer
WO2024116096A1 (en) 2022-12-01 2024-06-06 Pfizer Inc. Pneumococcal conjugate vaccine formulations
WO2024127215A2 (en) * 2022-12-13 2024-06-20 Pfizer Inc. Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile
CN117771361B (zh) * 2024-02-27 2024-06-07 天津中逸安健生物科技有限公司 一种聚肌苷酸-聚胞苷酸复合物的脂质纳米佐剂及其制备方法与应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4302459A (en) 1980-03-19 1981-11-24 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in leishmaniasis chemotherapy with 8-aminoquinoline derivatives
US5231112A (en) 1984-04-12 1993-07-27 The Liposome Company, Inc. Compositions containing tris salt of cholesterol hemisuccinate and antifungal
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US4684479A (en) 1985-08-14 1987-08-04 Arrigo Joseph S D Surfactant mixtures, stable gas-in-liquid emulsions, and methods for the production of such emulsions from said mixtures
US6759057B1 (en) 1986-06-12 2004-07-06 The Liposome Company, Inc. Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs
CN1093255A (zh) * 1986-06-17 1994-10-12 恩特雷麦德有限公司 抗甾醇疫苗
IE60901B1 (en) 1986-08-21 1994-08-24 Vestar Inc Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics
US6406713B1 (en) 1987-03-05 2002-06-18 The Liposome Company, Inc. Methods of preparing low-toxicity drug-lipid complexes
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
AU598958B2 (en) 1987-11-12 1990-07-05 Vestar, Inc. Improved amphotericin b liposome preparation
US5888519A (en) 1988-06-02 1999-03-30 The United States Of America As Represented By The Secretary Of The Army Encapsulated high-concentration lipid a compositions as immunogenic agents to produce human antibodies to prevent or treat gram-negative bacterial infections
US5215680A (en) 1990-07-10 1993-06-01 Cavitation-Control Technology, Inc. Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles
EP0761231B1 (en) * 1992-06-25 2000-01-12 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
AU5959494A (en) * 1992-12-29 1994-07-19 Entremed, Inc Vaccines against sterols
GB9320668D0 (en) * 1993-10-07 1993-11-24 Secr Defence Liposomes containing particulare materials
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6846489B1 (en) * 1995-04-25 2005-01-25 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol
ATE252372T1 (de) 1996-08-23 2003-11-15 Sequus Pharm Inc Liposome enthaltend cisplatin
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
EP0932390A1 (en) 1996-10-11 1999-08-04 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method
CA2276269C (en) 1996-10-15 2008-09-02 The Liposome Company, Inc. N-acyl phosphatidylethanolamine-mediated liposomal drug delivery
US6231859B1 (en) 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
GB9817052D0 (en) * 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
WO2008109398A1 (en) * 2007-03-01 2008-09-12 The Catholic University Of America T4 bacteriophage bound to a substrate
GB0910046D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
WO2012088414A1 (en) 2010-12-23 2012-06-28 Ludwig Institute For Cancer Research Ltd. Liposomal formulation of nonglycosidic ceramides and uses thereof

Also Published As

Publication number Publication date
JP2017515889A (ja) 2017-06-15
RU2016141622A (ru) 2018-04-25
JP6608422B2 (ja) 2019-11-20
US10434167B2 (en) 2019-10-08
AU2015236106A1 (en) 2016-10-20
CA2943190A1 (en) 2015-10-01
KR20170007242A (ko) 2017-01-18
WO2015148648A1 (en) 2015-10-01
SG11201607396WA (en) 2016-10-28
KR102242875B1 (ko) 2021-04-20
RU2016141622A3 (es) 2018-10-26
CN107124869A (zh) 2017-09-01
CN107124869B (zh) 2022-04-01
EP3122380B1 (en) 2025-03-19
US20170182152A1 (en) 2017-06-29
SG10201808315UA (en) 2018-10-30
EP3122380A1 (en) 2017-02-01

Similar Documents

Publication Publication Date Title
MX2016012168A (es) Formulacion adyuvante no toxica que comprende una composicion de liposoma que contiene monofosforil-lipido a (mpla) y una saponina.
CL2018001514A1 (es) Líquido higienizante de superficies en contacto con alimentos
CL2016001287A1 (es) Benzamidas sustituidas y procedimiento para su uso
MX2017003205A (es) Composiciones antimicrobianas y sus metodos de uso.
AR105401A1 (es) Mezcla acuosa que comprende un vector adenoviral, composición liofilizada, procedimiento
CL2014002564A1 (es) Composiciones para tratamiento de agua que comprende un coagulante que contiene aluminio y un polisacarido no derivado natural, en donde la relacion entre el polisacarido y el coagulante es entre 1:10 hasta 1:100; y métodos de uso.
AR086041A1 (es) Fluidos de tratamiento que contienen agentes quelantes biodegradables y metodos para utilizar los mismos
CL2014001060A1 (es) Compuestos derivados de aril-quinolina; proceso de obtencion; composicion farmaceutica que los comprende y uso en el tratamiento o profilaxis de la diabetes tipo 2, la aterosclerosis, cancer, entre otras enfermedades.
PE20151944A1 (es) Sistema de procesamiento por lotes multiples para la preparacion de una solucion de carbonato hidrogeno de calcio adecuada, para la remineralizacion de agua desalinizada y de agua blanda de origen natural
MX2016014564A (es) Vacuna contra la acinetobacter baumannii obtenida a partir de componentes celulares carentes de lipopolisacarido.
MX2016011176A (es) Polipeptidos fhbp meningococicos modificados.
CO6680654A2 (es) Composiciones y métodos para mejorar la compatibilidad de las sales herbicídas solubles en agua
CL2017000715A1 (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo
CL2015002488A1 (es) Sal de abexinostato novedosa, forma cristalina relacionada, método de preparación de esta y las composiciones farmacéuticas que la contienen
CL2015000608A1 (es) Formulaciones de daptomicina y usos de la misma
ECSP17005294A (es) Composición adhesiva
CO2017001902A2 (es) Adyuvantes acondicionadores del agua que promueven una baja volatilidad
CO6640213A2 (es) Comprimido de desintegración por vía oral que contiene acarbosa
CL2015000537A1 (es) Siarn y su uso en los métodos y composiciones para el tratamiento y/o prevención de enfermedades de los ojos.
CL2014001127A1 (es) Metodos y composicion de fumigante que comprende hexafluoropropeno, 1,1,3,3,3-pentafluoropropeno o combinacion de los mismos.
BR112013019924A2 (pt) composições para cuidado oral
UY35228A (es) Composiciones acuosas de cloquintocet-mexilo de temperatura estable
CL2014002658A1 (es) Composición inmunogénica que comprende proteínas de la membrana exterior de histophilus somni; usos y sus métodos de preparación.
CL2015002324A1 (es) Método para el tratamiento y control de enfermedades de postrecolección de frutas y hortalizas y composiciones que comprenden extractos naturales y formulaciones fitofortificantes y/o fungicidas para aplicar en dicho método.
AR103235A1 (es) Agente de turbidez a base de almidón para bebidas en polvo